A lively discussion between our region’s top innovators and connectors to hear about their efforts to help grow the innovation ecosystem and the pipeline of successful startups across the BioHealth Capital Region.
https://www.youtube.com/watch?v=Dn51Ga8jLrI&feature=youtu.be
Fourteen businesses in New Jersey’s technology, life sciences, and clean energy sectors received a combined $12.3 million from 50 investments approved through the state’s Angel Investor Tax Credit Program during the first half of 2020, the New Jersey Economic Development Authority (NJEDA) announced yesterday. Two of the approved companies benefited from legislation signed by Gov. Phil Murphy last year expanding the program.
The theme of the 25th CBA Annual (Virtual) Conference is “Innovations amid Crisis: A Productive Year of Biopharma Industry”. We will invite biopharmaceutical industry leaders, regulatory and scientific experts from US, China, and Canada to discuss recent research advances on COVID-19, and new trends in biopharma industry. The detailed conference program will be available at www.cba-usa.org shortly.
Time:
Day 1: 8 am – 11 am (EST), August 29th, 2020 (Saturday)
Day 2: 8 am – 11 am (EST), August 30th, 2020 (Sunday)
Registration link: https://bit.ly/2WfpRrR
The finalists are sourced from nominations and editorial coverage, and selected by the DC Inno team.
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer (CMO). Dr. Pierre Dodion, CMO since 2014, is retiring from this position.
Dr. Karakunnel comes to the Company with deep experience in immuno-oncology, and a proven track record in drug development. As CMO, he will be responsible for advancing Innate’s clinical pipeline and will lead a global team focused on clinical strategy, patient safety, regulatory and medical affairs.
Emergent BioSolutions revealed this week plans to expand its viral vector and gene therapy capabilities.
The company announced it will invest $75 million in its Canton, Mass., facility, which is focused on the contract development and manufacturing (CDMO) of drug substances for live viral vaccines, including the company’s smallpox vaccine
Healthcare stakeholders can no longer lag on digital transformation, and tapping into innovation can sate convenience-hungry consumers and tackle some massive challenges compressing their bottom lines.
Personalization and convenience have become table stakes in nearly every industry, and consumers are extending demands for these digital-powered experiences to healthcare — US consumers have expressed a willingness to jump ship to care services that can provide them with better digital experiences.
Image: Business Insider Intelligence
The raise is one of the biggest in the Triangle since last year.
Scientists have responded to COVID-19 with unprecedented speed. Just months after the outbreak of the novel coronavirus, clinical trials are already underway for nearly 200 vaccines and therapies.
But while the pace of COVID-19 innovation may be extraordinary, the research infrastructure allowing this remarkable work is hardly new. In fact, it was cemented into place nearly two generations ago when Congress passed the Bayh-Dole Act of 1980.
This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, Virginia Bio, Children’s National Health System, Johns Hopkins University, JPMorgan, Maryland Department of Commerce, George Mason University, University System of Maryland, Wilson Sonsini Goodrich & Rosati and AstraZeneca.
The BioHealth Capital Region—Maryland, Virginia, and Washington, DC—sets the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.
For more information about our speakers and event schedule, please visit www.biohealthcapital.com/forum-2020
#BHCRForum20
